RNA干涉市場

Abstract

Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA.

This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing. The main objectives of this study are to: 1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment; 2) obtain a complete understanding of the individual RNAi-testing platforms-from basic principles to clinical applications; 3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets; 4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and 5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.

Table of Contents

1. Overview

• 1.1 Objectives
• 1.2 Scope
• 1.3 Methodology
• 1.4 Executive Summary

2. RNA Interference (RNAi)

• 2.1 Introduction
• 2.2 Overview of RNA Interference
  • 2.2.1 Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA
  • 2.2.2 Mechanism of RNAi In Vivo
• 2.3 Glossary
• 2.4 What Areas of Research Does RNAi Impact?
  • 2.4.1 RNAi Technology in Life Sciences Research, Drug Discovery and Development
    • 2.4.1.1 Clinical Trials Featuring RNAi-based Therapeutics
  • 2.4.2 RNAi Technology in Agriculture
    • 2.4.2.1 Companies Utilizing RNAi Technology for Agriculture

3. Technology Trends in RNAi Space

• 3.1 Overview
• 3.2 End-User Segmentation
• 3.3 Technologies for Inducing RNAi
  • 3.3.1 Methods for Detecting Gene Silencing
  • 3.3.2 Libraries of siRNAs/shRNAs to Knockdown Genes En Masse
    • 3.3.2.1 Publicly Available Large-scale Mammalian RNAi Libraries
    • 3.3.2.2 The RNAi Consortium (TRC)
    • 3.3.2.3 RNAi-related Consortia Based in Europe
  • 3.3.3 Comparison of Strategies for Target Validation
    • 3.3.3.1 Market Shifts in RNAi Space: Where Is It Headed?
    • 3.3.3.2 Intellectual Property and Patent Issues
    • 3.3.3.3 Funding in RNAi Space: Grants, Venture Capital and IPOs
    • 3.3.3.4 Partnerships, Alliances, Mergers and Acquisitions
  • 3.3.4 miRNA-Based RNAi: Leading Edge of RNAi Space
    • 3.3.4.1 Biological Function of miRNAs
    • 3.3.4.2 Role of miRNAs in Disease

4. RNAi Market Analysis

• 4.1 Overview
• 4.2 Market Data Collection and Respondent Pool
  • 4.2.1 Respondent Pool Characteristics
• 4.3 RNAi Technologies/Products in Research Applications
• 4.4 RNAi Technologies/Products: Market Shares (Quantitative)
• 4.5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth
  • 4.5.1 Growth of Various Segments in RNAi Space
  • 4.5.2 Product Formats and Representation in RNAi Marketplace
• 4.6 RNAi Marketplace: Challenges, Unmet Needs and Drivers
  • 4.6.1 Unmet Needs in RNAi Space
  • 4.6.2 RNAi Market: Qualitative Growth Drivers

5. The RNAi Landscape

• 5.1 Overview
• 5.2 Market Segmentation of RNAi and Segment Characteristics
• 5.3 Quantitative Market Opportunities in RNAi Space
  • 5.3.1 Opportunities in miRNA Space
  • 5.3.2 Opportunities in siRNA/shRNA Space
• 5.4 RNAi Product Offerings and Associated Business Models

6. Company Profiles

• 6.1 Alfacell Corporation
• 6.2 Allele Biotechnology and Pharmaceuticals, Inc.
• 6.3 Alnylam Pharmaceuticals
• 6.4 Ambion
• 6.5 Applied Biosystems Group
• 6.6 Asuragen, Inc.
• 6.7 Avalon Pharmaceuticals, Inc.
• 6.8 B-Bridge International, Inc.
• 6.9 Bio-Rad Laboratories
• 6.10 Calando Pharmaceuticals, Inc.
• 6.11 Cepheid
• 6.12 Cequent
• 6.13 Clontech Laboratories, Inc.
• 6.14 CombiMatrix Corporation
• 6.15 Cyntellect, Inc.
• 6.16 CytRx Corp.
• 6.17 Dharmacon
• 6.18 Dicerna
• 6.19 Galenea Corporation
• 6.20 GeneCopoeia, Inc.
• 6.21 GeneThera, Inc.
• 6.22 Genlantis
• 6.23 GenoSensor
• 6.24 GRL, Inc.
• 6.25 IDT
• 6.26 Imgenex Corporation
• 6.27 Ingenuity Systems
• 6.28 Isis Pharmaceuticals, LLC
• 6.29 Intradigm Corporation
• 6.30 Invitrogen
• 6.31 InvivoGen
• 6.32 LC Sciences
• 6.33 Lentigen Corporation
• 6.34 Merck & Co., Inc.
• 6.35 Mirus Bio Corporation
• 6.36 Monsanto
• 6.37 Nastech Pharmaceutical Company, Inc.
• 6.38 New England BioLabs
• 6.39 Nucleonics, Inc.
• 6.40 Open Biosystems, Inc.
• 6.41 OPKO Health, Inc.
• 6.42 OriGene
• 6.43 Panomics, Inc.
• 6.44 PhaseRx
• 6.45 Promega Corp.
• 6.46 Quark Pharmaceuticals, Inc.
• 6.47 RXi Pharmaceuticals Corporation
• 6.48 Senetek PLC
• 6.49 Sigma-Aldrich
• 6.50 Sirna Therapeutics
• 6.51 Sirnaomics, Inc.
• 6.52 SomaGenics, Inc.
• 6.53 System Biosciences
• 6.54 Tacere Therapeutics
• 6.55 Targeted Genetics Corporation
• 6.56 Third Wave Technologies
• 6.57 Traversa
• 6.58 Actigenics SA
• 6.59 Amaxa
• 6.60 AstraZeneca PLC
• 6.61 Cenix Bioscience GmbH
• 6.62 deVGen N.V.
• 6.63 DNAVision
• 6.64 Exiqon
• 6.65 Genovis
• 6.66 genOway
• 6.67 imaGenes GmbH
• 6.68 MWG Biotech AG
• 6.69 OZ Biosciences
• 6.70 Prosensa Holding
• 6.71 QIAGEN
• 6.72 RNAx GmbH (Germany)
• 6.73 Roche
• 6.74 Rosetta Genomics, Ltd.
• 6.75 Santaris Pharma A/S
• 6.76 Silence Therapeutics PLC
• 6.77 TaconicArtemis GmbH
• 6.78 TRANSAT
• 6.79 alphaGEN Co., Ltd.
• 6.80 Benitec, Ltd.
• 6.81 Bioneer
• 6.82 CytoPathfinder, Inc.
• 6.83 Genesis Research & Development Corp.
• 6.84 GeneDesign, Inc.
• 6.85 GNI Pharmaceutical Corporation
• 6.86 Koken Co., Ltd.
• 6.87 NanoCarrier Co., Ltd.
• 6.88 Oncolys Biopharma, Inc.
• 6.89 RealGene Bio-Technologies, Inc.
• 6.90 Samchully Pharmaceuticals
• 6.91 Samyang Corp.
• 6.92 Shanghai Biochip
• 6.93 Shanghai GenePharma Co.
• 6.94 Shanghai Genomics, Inc.
• 6.95 Transgene Biotek, Ltd.
• 6.96 Tekmira

INDEX OF TABLES

• Table 2.1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells
• Table 2.2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature
• Table 2.3: RNAi-based Therapeutics in Clinical Trials
• Table 2.4: Suppliers of Enabling Technologies and Tools in RNAi Space
• Table 2.5: Suppliers of siRNA/shRNA Products (by Product/Service Class)
• Table 3.1: Currently Utilized Technologies for Inducing RNAi-Mediated Knockdown
• Table 3.2: Comparison of mRNA Detection Technologies
• Table 3.3: Characteristics of Various Publicly available Mouse and Human RNAi Libraries
• Table 3.4: Comparison of Formats for Library-Based Gene Knockdown
• Table 3.5: Strategies for Target Validation by Pharma/Biotech: RNAi and Others
• Table 3.6: Seminal Patents in RNAi
• Table 3.7: Venture Capital Raised by Selected Companies in the RNAi Space
• Table 3.8: List of Public Biotech Companies in RNAi Space
• Table 3.9: Disease-Related miRNAs
• Table 3.10: Publicly Available Computational Programs for Identifying miRNA Sequences/Targets
• Table 3.11: SWOT Analysis of siRNA Oligonucleotides
• Table 3.12: Transfection Reagents (Lipid-Mediated Delivery)
• Table 3.13: shRNA Plasmid Constructs
• Table 3.14: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery)
• Table 5.1: RNAi Market Segmentation and Research Settings
• Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies
• Table 5.3: Segment 2: RNAi for Drug Discovery and Development
• Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics
• Table 5.5: Segment 4: RNAi Fee-for-Service Business
• Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005-2008
• Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006-2009

INDEX OF FIGURES

• Figure 2.1: The miRNA Processing Pathway
• Figure 2.2: Growth of Scientific Publications Addressing miRNAs, 2001-2008
• Figure 2.3: Mechanisms of Small RNA-induced Gene Regulation
• Figure 2.4: Types of RNAi Compounds
• Figure 2.5: Breakdown of Scientific Publications Related to RNAi by Geographic Region, 2007-2008
• Figure 3.1: End-User Segmentation of RNAi Space
• Figure 3.2: RNAi Patents Filed Globally, by Geographical Origin
• Figure 3.3: Selected Deals in RNAi Space
• Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents
• Figure 4.2: Affiliation of RNAi End-User Survey Respondents
• Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool
• Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool
• Figure 4.5: Research Applications Using RNAi Technologies/Products
• Figure 4.6: Types of RNAi Technologies Currently Utilized
• Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users
• Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months
• Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies
• Figure 4.10: Number of Experiments Involving RNAi Conducted per Week
• Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research
• Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used
• Figure 4.13: Current RNAi Market Share by Segments
• Figure 4.14: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months)
• Figure 4.15: Product Formats Utilization for RNAi Research (Current and Six to 18 Months)
• Figure 4.16: Companies Offering Product Formats for Currently Used RNAi Products
• Figure 4.17: RNAi Product Offerings/Formats Use (Projections-Six to 18 Months)
• Figure 4.18: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months)
• Figure 4.19: Key Challenges Faced by End-Users in RNAi Space
• Figure 4.20: Unmet Needs in RNAi Space Ranked by Importance to End-Users
• Figure 5.1: Growth and Evolution of miRNA Space
• Figure 5.2: Elements of RNAi Value Chain
• Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space
• Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm